Neha Mishra, Ph.D, Senior Scientist Bioproduction, Revvity.
Monoclonal antibodies (mAb) have established themselves as one of the leading classes of biotherapeutics, making up over 50% of first-time regulatory approvals in recent years. With total mAb sales expected to surpass US$200 billion in 2024, many companies and academic researchers are investing significantly into methods to enhance the therapeutic properties of these proteins.